Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Santhera: phase‑1 topline for AGAMREE® shows glucocorticoid activity without meaningful immunosuppression
Santhera reports topline results from a Phase‑1 study of AGAMREE® conducted by Catalyst, which show glucocorticoid and anti‑inflammatory effects at clinical doses but only minor immunosuppressive biomarker effects. Relevant immunosuppressive effects were observed only at doses above the currently approved AGAMREE dosage. Catalyst holds North American rights for DMD and potential follow‑on indications; Santhera retains pre‑negotiation rights outside North America and is entitled to sales‑based milestones and royalties. » Altro su finanzen.net
Santhera reports 98% revenue growth in 2025 driven by AGAMREE
Santhera recorded a 98% increase in total revenue in 2025 to CHF 77.4 million, driven by strong uptake of AGAMREE in Europe and the US as well as license and milestone receipts. Product sales rose to CHF 25.8 million and license and milestone payments to CHF 23.1 million; Catalyst paid a milestone of USD 12.5 million after US sales exceeded USD 100 million. After year-end, Santhera signed an exclusive license agreement with Nxera worth up to USD 205 million, which included an upfront payment of USD 40 million. Cash and cash equivalents amounted to CHF 22.4 million as of 31.12.2025 (excluding the Nxera upfront), and the company expects cash-flow break-even in Q3 2026 without additional financing. » Altro su finanzen.net
Santhera appoints Marc Clausse as chief commercial officer
Santhera Pharmaceuticals has appointed Marc Clausse as chief commercial officer (CCO). Clausse will assume responsibility for leading the company’s commercial activities. » Altro su finanzen.net
Santhera closes $13m royalty agreement to support AGAMREE
Santhera has confirmed the closing of a $13 million royalty agreement announced in September with R-Bridge and the Partners Group. The agreement covers 25% of net royalties for AGAMREE from Catalyst in North America and from Sperogenix in China; payments are limited and will revert to Santhera after a cap or a set term is reached. Santhera retains a buyback right for the royalties and will use the funds to finance the global launch of AGAMREE. » Altro su finanzen.net
Santhera: long-term analysis confirms improved safety profile of AGAMREE in Duchenne muscular dystrophy
Santhera reports positive topline results from a long-term analysis of the ongoing, open-label, multicenter GUARDIAN study of AGAMREE (vamorolone) in patients with Duchenne muscular dystrophy (DMD). The data confirm an improved safety profile for AGAMREE. Further details are set out in the full study. » Altro su finanzen.net
Dati finanziari
Nell'ultimo trimestre, Santhera Pharma Aktie ha registrato ricavi pari a 52,36 Mln € e un utile netto di -23,32 Mln €
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 52,36 Mln | - |
| Utile lordo | 19,44 Mln | - |
| Utile netto | -23,32 Mln | - |
| EBITDA | -4,16 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 215,78 Mln € |
Numero di azioni | 15,31 Mln |
Massimo/minimo a 52 settimane | 20,30 € - 12,69 € |
| Dividendi | No |
Beta | -0,28 |
Rapporto P/E | -5,58 |
Rapporto PEG | -0,07 |
Rapporto P/B | -29,57 |
Rapporto P/S | 1,92 |
Profilo aziendale
Santhera Pharmaceuticals Holding AG, un'azienda farmaceutica specializzata che, insieme alle sue controllate, sviluppa e commercializza farmaci per malattie neuromuscolari e polmonari rare con un elevato bisogno medico non soddisfatto nell'Unione Europea e a livello internazionale. Il principale candidato della pipeline dell'azienda è il vamorolone, in fase di sviluppo come trattamento per la distrofia muscolare di Duchenne (DMD). La pipeline in fase clinica comprende anche il lonodelestat (POL6014) per il trattamento della fibrosi cistica e di altre malattie polmonari neutrofiliche, nonché l'omigapil, che tratta le distrofie muscolari congenite. L'azienda concede inoltre in out-licensing i diritti al di fuori del Nord America e della Francia per il proprio prodotto approvato, Raxone (idebenone), destinato al trattamento della neuropatia ottica ereditaria di Leber. Santhera Pharmaceuticals Holding AG è stata fondata nel 2004 ed ha sede a Pratteln, in Svizzera.
| Nome | Santhera Pharma Aktie |
| CEO | Orlando Oliveira |
| Sede centrale | Pratteln,
bl Svizzera |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 06/03/2014 |
| Dipendenti | 78 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
SIX | SANN.SW |
London Stock Exchange | 0QN1.L |
Pnk | SPHDF |
London | 0QN1.L |